Idioma:

A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia

Brodszky, Valentin ; Rencz, Fanni ; Péntek, Márta ; Baji, Petra ; Lakatos, Péter L ; Gulácsi, László

Expert review of pharmacoeconomics & outcomes research, 2016-01, Vol.16 (1), p.119-125 [Periódico revisado por pares]

England: Taylor & Francis

Sem texto completo

Citações Citado por

Enviar para

Título:
A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia
Autor: Brodszky, Valentin ; Rencz, Fanni ; Péntek, Márta ; Baji, Petra ; Lakatos, Péter L ; Gulácsi, László
Assuntos: biosimilar drugs ; Biosimilar Pharmaceuticals - administration & dosage ; Biosimilar Pharmaceuticals - economics ; budget impact analysis ; Budgets ; Central and Eastern Europe ; Cost Savings ; Crohn Disease - drug therapy ; Crohn Disease - economics ; Crohn's disease ; Europe, Eastern ; Gastrointestinal Agents - administration & dosage ; Gastrointestinal Agents - economics ; Humans ; inflammatory bowel diseases ; infliximab ; Infliximab - administration & dosage ; Infliximab - economics ; Insurance, Health, Reimbursement - economics ; Models, Economic
É parte de: Expert review of pharmacoeconomics & outcomes research, 2016-01, Vol.16 (1), p.119-125
Descrição: Objectives: To estimate the budget impact of the introduction of biosimilar infliximab for the treatment of Crohn's disease (CD) in Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. Methods: A 3-year, prevalence-based budget impact analysis for biosimilar infliximab to treat CD was developed from third-party payers' perspective. The model included various scenarios depending on whether interchanging originator infliximab with biosimilar infliximab was allowed or not. Results: Total cost savings achieved in biosimilar scenario 1 (interchanging not allowed) and BSc2 (interchanging allowed in 80% of the patients) were estimated to €8.0 million and €16.9 million in the six countries. Budget savings may cover the biosimilar infliximab therapy for 722-1530 additional CD patients. Conclusions: Introduction of biosimilar infliximab to treat CD may offset the inequity in access to biological therapy for CD between Central and Eastern European countries.
Editor: England: Taylor & Francis
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia

Brodszky, Valentin ; Rencz, Fanni ; Péntek, Márta ; Baji, Petra ; Lakatos, Péter L ; Gulácsi, László

England: Taylor & Francis

Buscando em bases de dados remotas. Favor aguardar.